TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
News|Podcasts|August 20, 2025
The Weekly Dose: Nutrition Gaps, Tau Pathology in Mood Disorders, RSV Protection, and More
Author(s)Sydney Jennings
Fact checked by: Grace Halsey
This week’s roundup covers nutrition counseling barriers, tau pathology in mood disorders, RSV protection, AD patient needs, and a new Shingrix syringe.
Advertisement
Welcome to this week’s comprehensive breakdown of The Weekly Dose, your essential source for the latest updates in medicine and clinical care. This episode covers a diverse range of topics—from nutrition counseling and neurodegenerative research to breakthrough RSV prevention, patient-centered dermatology, and vaccine delivery innovations. Above, we’ll dive deep into each story, unpacking the nuances, expert insights, and actionable recommendations that clinicians can apply in their practice.
EPISODE BREAKDOWN
Editor's note: Episode timestamps produced using AI tools.
- Nutrition Counseling Insights (00:00:11): Global survey of clinicians on diet recommendations, barriers to counseling, and concerns about fad diets and food safety.
- Neurodegenerative Pathologies in Mood Disorders (00:01:26): Research on Alzheimer’s and non-Alzheimer’s tau pathologies in late-life depression and bipolar disorder, emphasizing diagnostic implications.
- RSV Prevention in Infants (00:01:26): Large study on nirsevimab’s effectiveness in preventing RSV in healthy term infants, supporting current recommendations.
- Patient Priorities in Atopic Dermatitis (00:02:52): Survey on patient experiences, misdiagnosis rates, treatment goals, and interest in personalized approaches for atopic dermatitis.
- Prefilled Syringe for Shingles Vaccine (00:04:10): FDA approval of a new prefilled syringe formulation for the recombinant zoster vaccine, simplifying administration for shingles prevention.
Advertisement
Related to this article
JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.
TMS 2026: Women exercising at least 5 days a week reported lower perimenopause symptom scores across psychological, somatic, and urogenital domains.
TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.
TMS 2026: In ARIC, menopause before age 40 was linked to higher CVD and CHD risk, with insulin resistance mediating about 19% of the association.
TMS 2026: Post hoc OASIS 1 and 2 data show more women on elinzanetant reported improvement across all 8 PROMIS sleep disturbance items vs placebo at week 12.
In a pilot study of 20 midlife women with vasomotor symptoms, an AI-enabled VR program delivering CBT showed early feasibility and acceptability.
Advertisement
Advertisement
Trending on Patient Care Online
1
Menopause Hormone Therapy Linked to Greater Weight Loss With Semaglutide in Real-World Study
2
Menopause Diagnoses Documented in Just 7.8% of Midlife Women's Outpatient Visits, Study Finds
3
JoAnn Pinkerton, MD, on Counseling Patients Starting Elinzanetant for VMS
4
Fezolinetant May Improve Depression, Anxiety Symptoms in Women With Menopausal VMS
5